LexaGene Reports on Recent Veterinary Trade Shows
September 30 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a commercial molecular diagnostics
company selling a point-of-need highly multiplexed in-clinic PCR
system with results in approximately two hours, today provided an
update on the three veterinary conferences attended by the Company
in September.
During the month of September, the Company
exhibited at the WVC Annual Conference, the International
Veterinary Emergency and Critical Care Conference (IVECCS), and the
Southwest Veterinary Symposium (SWVS).
Dr. Jack Regan, LexaGene’s CEO and Founder
stated, “At these shows, we believe that we had one of the busiest
booths due to the uniqueness of our technology. We are happy to
report that during these shows and through our digital marketing
campaign, we have generated more than 750 leads during the month of
September and have added to our number of sales. The sheer number
of booth visitors and the excitement they showed over our
technology has hardened our stance that in-clinic PCR testing will
soon become common place in veterinary medicine. These shows marked
the first time LexaGene demonstrated - in person - the usability
and features of our MiQLab® System. Universally, visitors showed
excitement over the availability of our system that automates PCR
testing for pathogen identification and anti-microbial resistance
detection.”
Dr. Regan continued, “Visitors at our booths
included practice managers, veterinarians, veterinary technicians,
and corporate decision makers. Our sales reps are actively
following up with these individuals and are optimistic about
closing many additional sales from these conferences. As most
visitors first learned of LexaGene and our product at these shows,
we need to allow sufficient time for closing the many opportunities
that these shows provided us.”
During these last two weeks, Dr. Jack Regan and
Mr. Jeffrey Mitchell, LexaGene’s CFO, were able to have
conversations with personnel at some of the biggest veterinary
health companies, who expressed interest in the MiQLab. The sales
cycle for corporate accounts, where substantial multi-unit orders
is possible, is significantly longer than at private practices, as
there are often large purchasing committees rather than one or just
a few decision makers. We heard from some of these corporate
individuals that fighting antimicrobial resistance via better
diagnostics is a priority for their hospitals. To our knowledge, we
were the only company at these tradeshows selling a product capable
of both multi-pathogen detection and screening for numerous first
line antimicrobial resistance factors at the point of care. These
attributes made us stand out as a new and exciting company offering
a revolutionary technology for the veterinary space.
Mr. Jeffrey Mitchell, LexaGene’s CFO stated,
“These conferences have re-affirmed our belief that there is strong
demand for this technology, and we believe we can become a market
leader for in-clinic infectious disease testing. We feel great
about the excitement veterinarians showed for our technology and we
can leverage this enthusiasm as we focus on closing sales.”
To view Dr. Regan’s comments on these
conferences, please click HERE.
To view Dr. Regan’s presentation at WVC, click
HERE.To view Dr. Nair’s presentation at SWVS, click HERE.To view
Dr. Eric DiBasio’s poster presented at IVECCS, click HERE.
To learn more about LexaGene and the MiQLab
System or subscribe to company updates, visit www.lexagene.com, or
follow us on Twitter or LinkedIn.
On Behalf of the Board of
DirectorsDr. Jack ReganChief
Executive Officer & Chairman
About LexaGene Holdings
Inc.LexaGene is a molecular diagnostics company that
develops molecular diagnostic systems for pathogen detection and
genetic testing for other molecular markers for on-site rapid
testing in veterinary diagnostics, food safety and for use in
open-access markets such as clinical research, agricultural
testing, and biodefense. End-users simply need to collect a sample,
load it onto the instrument with a sample preparation cartridge,
enter sample ID and press ‘go’. The MiQLab™ system delivers
excellent sensitivity, specificity, and breadth of detection and
can return results in approximately two hours. The unique
open-access feature is designed for custom testing so that
end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors -- including the
availability of funds, the results of financing efforts, the
success of technology development efforts, the cost to procure
critical parts, performance of the instrument, market acceptance of
the technology, regulatory acceptance, and licensing issues -- that
could cause actual results to differ materially from the Company's
expectations as disclosed in the Company's documents filed from
time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Corporate & Media Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Investors:
Sharon Choe
Vice President
LaVoieHealthScience
schoe@lavoiehealthscience.com
(857) 241-7393
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024